Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Nov 27

PMID 39596288

Authors

Jing Wang

Yuanli He

Feiming Hu

Chenchen Hu

Yuanjie Sun

Kun Yang

Shuya Yang

Affiliations

Soon will be listed here.

Abstract

Metabolic reprogramming of immune cells within the tumor microenvironment (TME) plays a pivotal role in shaping tumor progression and responses to therapy. The intricate interplay between tumor cells and immune cells within this ecosystem influences their metabolic landscapes, thereby modulating the immune evasion tactics employed by tumors and the efficacy of immunotherapeutic interventions. This review delves into the metabolic reprogramming that occurs in tumor cells and a spectrum of immune cells, including T cells, macrophages, dendritic cells, and myeloid-derived suppressor cells (MDSCs), within the TME. The metabolic shifts in these cell types span alterations in glucose, lipid, and amino acid metabolism. Such metabolic reconfigurations can profoundly influence immune cell function and the mechanisms by which tumors evade immune surveillance. Gaining a comprehensive understanding of the metabolic reprogramming of immune cells in the TME is essential for devising novel cancer therapeutic strategies. By targeting the metabolic states of immune cells, it is possible to augment their anti-tumor activities, presenting new opportunities for immunotherapeutic approaches. These strategies hold promise for enhancing treatment outcomes and circumventing the emergence of drug resistance.

Citing Articles

Recombinant α-Toxin BmK-M9 Inhibits Breast Cancer Progression by Regulating β-Catenin In Vivo.

Chen W, Cha Z, Huang S, Liu R, Chen J, Kamau P Cell Biochem Biophys. 2025; .

PMID: 40080350 DOI: 10.1007/s12013-025-01711-8.

Current advancement of immune function paradox of tumour-infiltrating cells and their immunotherapeutic targets: a mini-review.

Tom V, Jose A, Mallick S, Sasidharan A, Pawar R, Somayaji Y Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40063239 DOI: 10.1007/s00210-025-03985-4.

Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.

Suri C, Pande B, Suhasini Sahithi L, Swarnkar S, Khelkar T, Verma H Cancer Drug Resist. 2025; 8:7.

PMID: 40051496 PMC: 11883236. DOI: 10.20517/cdr.2024.164.

Advancements in targeted and immunotherapy strategies for glioma: toward precision treatment.

Gong G, Jiang L, Zhou J, Su Y Front Immunol. 2025; 15:1537013.

PMID: 39877359 PMC: 11772277. DOI: 10.3389/fimmu.2024.1537013.

References

Gabrilovich D . Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004; 4(12):941-52. DOI: 10.1038/nri1498. View

Song H, Song J, Cheng M, Zheng M, Wang T, Tian S . METTL3-mediated mA RNA methylation promotes the anti-tumour immunity of natural killer cells. Nat Commun. 2021; 12(1):5522. PMC: 8448775. DOI: 10.1038/s41467-021-25803-0. View

Long Y, Tao H, Karachi A, Grippin A, Jin L, Chang Y . Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. Cancer Res. 2019; 80(3):499-509. DOI: 10.1158/0008-5472.CAN-19-1577. View

Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N . The cancer metabolic reprogramming and immune response. Mol Cancer. 2021; 20(1):28. PMC: 7863491. DOI: 10.1186/s12943-021-01316-8. View

Lowe M, Boothby I, Clancy S, Ahn R, Liao W, Nguyen D . Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues. JCI Insight. 2019; 4(24). PMC: 6975275. DOI: 10.1172/jci.insight.129756. View

Veglia F, Tyurin V, Blasi M, De Leo A, Kossenkov A, Donthireddy L . Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature. 2019; 569(7754):73-78. PMC: 6557120. DOI: 10.1038/s41586-019-1118-2. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

Cronin S, Seehus C, Weidinger A, Talbot S, Reissig S, Seifert M . The metabolite BH4 controls T cell proliferation in autoimmunity and cancer. Nature. 2018; 563(7732):564-568. PMC: 6438708. DOI: 10.1038/s41586-018-0701-2. View

Wilson J, Ross W, Agbai O, Frazier R, Figler R, Rieger J . The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J Immunol. 2009; 182(8):4616-23. PMC: 2989878. DOI: 10.4049/jimmunol.0801279. View

10.

Zhu G, Tang Z, Huang R, Qu W, Fang Y, Yang R . CD36 cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discov. 2023; 9(1):25. PMC: 9988869. DOI: 10.1038/s41421-023-00529-z. View

11.

Kao K, Vilbois S, Tsai C, Ho P . Metabolic communication in the tumour-immune microenvironment. Nat Cell Biol. 2022; 24(11):1574-1583. DOI: 10.1038/s41556-022-01002-x. View

12.

Geiger R, Rieckmann J, Wolf T, Basso C, Feng Y, Fuhrer T . L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. Cell. 2016; 167(3):829-842.e13. PMC: 5075284. DOI: 10.1016/j.cell.2016.09.031. View

13.

Mullen P, Yu R, Longo J, Archer M, Penn L . The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer. 2016; 16(11):718-731. DOI: 10.1038/nrc.2016.76. View

14.

Shi L, Feng M, Du S, Wei X, Song H, Yixin X . Adenosine Generated by Regulatory T Cells Induces CD8 T Cell Exhaustion in Gastric Cancer through A2aR Pathway. Biomed Res Int. 2020; 2019:4093214. PMC: 6942766. DOI: 10.1155/2019/4093214. View

15.

Thommen D, Schumacher T . T Cell Dysfunction in Cancer. Cancer Cell. 2018; 33(4):547-562. PMC: 7116508. DOI: 10.1016/j.ccell.2018.03.012. View

16.

Revilla S, Kranenburg O, Coffer P . Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting. Front Immunol. 2022; 13:903564. PMC: 9304750. DOI: 10.3389/fimmu.2022.903564. View

17.

Wang L, Zhu L, Liang C, Huang X, Liu Z, Huo J . Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis. J Hepatol. 2023; 79(5):1185-1200. DOI: 10.1016/j.jhep.2023.06.021. View

18.

Shi S, Lee E, Lin Y, Chen L, Zheng H, He X . Recruitment of monocytes and epigenetic silencing of intratumoral CYP7B1 primarily contribute to the accumulation of 27-hydroxycholesterol in breast cancer. Am J Cancer Res. 2019; 9(10):2194-2208. PMC: 6834472. View

19.

Chen C, Zhao F, Peng J, Zhao D, Xu L, Li H . Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8 T cell exhaustion and anti-PD-1 resistance. Cell Rep Med. 2024; 5(8):101686. PMC: 11384939. DOI: 10.1016/j.xcrm.2024.101686. View

20.

Liu H, Shen Z, Wang Z, Wang X, Zhang H, Qin J . Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. Sci Rep. 2016; 6:21319. PMC: 4758033. DOI: 10.1038/srep21319. View